| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future? | Ben Fidler | 08/08/18 | San Francisco |
| Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More | Alex Lash | 12/09/16 | National |
| Acetylon Crafts New Buyout Deal With Celgene, Spins Out Startup Regenacy | Ben Fidler | 12/02/16 | Boston |
| Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More | Ben Fidler | 08/12/16 | National |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| East Coast Bio Roundup: NY Startups, Editas, Bonney, C4 & (Much) More | Ben Fidler | 01/08/16 | Boston |
| Tech Mogul, Patriots Owner Lavish $73M On Dana-Farber Startup | Ben Fidler | 01/07/16 | Boston |
| Celgene, Versant Shake Again, Cut $30M Deal For Toronto Biotech | Alex Lash | 04/29/15 | New York |
| East Coast Biotech Roundup: Juno, Editas, Celgene, & More | Ben Fidler | 12/06/13 | Boston |
| Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs | Ben Fidler | 12/03/13 | San Francisco |
| Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker | Luke Timmerman | 08/05/13 | National |
| East Coast Biotech Roundup: Cubist, Acetylon, Foundation, & More | Ben Fidler | 08/02/13 | Boston |
| Acetylon Pharmaceuticals Obtains $100,000,000 New Funding Round | VentureDeal | 07/30/13 | Boston |
| Celgene Nabs Option to Buy Acetylon for More Than $1.7B | Ben Fidler | 07/29/13 | Boston |
| Synchroneuron, Radius, Acetylon, & More Boston Life Sciences News | Erin Kutz | 02/10/12 | Boston |
| Acetylon Pharmaceuticals Secures $15,000,000 New Round | VentureDeal | 02/09/12 | Boston |
| RXi Splits Up, Zeo Launches Mobile Sleep-Tracking App, Karuna Licenses Schizophrenia Compounds, & More Boston-Area Life Sciences News | Erin Kutz | 09/30/11 | Boston |
| Backed by Eclectic Financiers, Acetylon Begins Trials of Cancer Drug | Arlene Weintraub | 09/27/11 | Boston |
| Zynga Files For IPO, Brightcove Inks Boston Lease, Lotus Adds $26M, & More Boston-Area Deals News | Erin Kutz | 07/06/11 | Boston |
| Acetylon Adds $27M, Third Rock Leads Lotus Round, InfraReDx Gets $24M, & More Boston-Area Life Sciences News | Erin Kutz | 07/01/11 | Boston |
| Acetylon, Backed by Patriots Owner Bob Kraft, Snags $27M to Develop New Cancer Drugs | Luke Timmerman | 06/29/11 | Boston |
| Acetylon Pharmaceuticals Receives $14,600,000 Series B Round | VentureDeal | 06/29/11 | Boston |
| GSK Backs SpringLeaf, Prexa Nabs $7M from Advent & Shire, Acetylon Gets $5M Partnership, & More Boston-Area Life Sciences News | Erin Kutz | 05/13/11 | Boston |
| Acetylon Nabs $4.9M for Myeloma Drug | Luke Timmerman | 05/11/11 | Boston |
| Constant Contact Buys Bantam Live, Forest Pays $1.2B for Clinical Data, Paydiant Scores $7.6M, & More Boston-Area Deals News | Erin Kutz | 02/23/11 | Boston |
| Acetylon Pharma Raises $12.4M | Ryan McBride | 02/22/11 | Boston |
| Acetylon Pharmaceuticals Secures $12,400,000 Series B Financing Round | VentureDeal | 02/22/11 | Boston |
| Constellation Pharma Hires New CEO, Collects Last $17M of its Series A Financing | Ryan McBride | 08/13/09 | Boston |
| Biogen Idec Faces Suit From Partner Elan, Genzyme Wins European Approval for Stem-Cell Boosting Drug, Alnylam Teams with Tekmira, & More Boston-Area Life Sciences News | Rebecca Zacks | 08/12/09 | Boston |
